SNDXSyndax Pharmaceuticals, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SNDX?
Syndax Pharmaceuticals, Inc. keeps −77% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +3.1%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 104%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −4708% |
| FY2021 | 19% |
| FY2024 | −1434% |
| FY2025 | −158% |
Details›
- Operating margin12 months to Q2 2026
- −77%
- Net margin12 months to Q2 2026
- −88%
- R&D as % of revenue
- 104%
- Revenue, trailing twelve months
- $252M
- Net income, trailing twelve months
- −$221M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.